The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
A Prospective, Randomized Trial of Calcineurin-Inhibitor Withdrawal in Renal Allograft Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Living and deceased donor kidney transplant recipients at the Mayo Clinic, Rochester, Minnesota
Exclusion Criteria:
- Patients with type 1 diabetes less than 50 years of age who receive a living donor kidney transplant followed by a pancreas transplant
- Pediatric patients (<18 years of age)
- Multi-organ transplants (e.g., kidney-pancreas, kidney-liver)
- ABO-incompatible or positive crossmatch recipients (ABO incompatibility is an immune system reaction that occurs when blood from two different and incompatible blood types are mixed together.)
- Patients with severe hyperlipidemia (serum cholesterol >350 mg/dl or serum triglycerides >500 mg/dl
- Patients with severe leukopenia (White Blood Cell count [WBC]<3000 10^3/ml)
- Patients unwilling to return to the transplant center for late follow-up visits
- Body mass index (BMI) ≥ 32 with incisional problems post transplant (as determined by renal transplant surgeon
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Tacrolimus
Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
|
Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
Other Names:
Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
Other Names:
Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
Other Names:
Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
Other Names:
|
|
Active Comparator: Sirolimus
Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
|
Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
Other Names:
Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
Other Names:
Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
Other Names:
Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glomerular filtration rate (GFR) (iothalamate clearance) at 12 months following transplantation
Time Frame: 12 months following transplantation
|
Glomerular filtration rate (Iothalamate clearance) at 12 months following transplantation.
|
12 months following transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
GFR (iothalamate clearance) at other time points
Time Frame: 24 months
|
24 months
|
|
Other measures of renal function (serum creatinine, proteinuria and albuminuria)
Time Frame: 24 months
|
24 months
|
|
Acute rejection both early and after tacrolimus withdrawal
Time Frame: 24 months
|
24 months
|
|
Patient and graft survival
Time Frame: 24 months after transplantation
|
24 months after transplantation
|
|
Complications-especially hypertension, diabetes, dyslipidemia
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Dean PG, Grande JP, Sethi S, Park WD, Griffin MD, Cosio FG, Larson TS, Stegall MD. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation. 2008 Apr 27;85(8):1212-5. doi: 10.1097/TP.0b013e31816a8ae6.
- Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant. 2006 Mar;6(3):514-22. doi: 10.1111/j.1600-6143.2005.01177.x.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Kidney Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Prednisone
- Tacrolimus
- Mycophenolic Acid
- Sirolimus
- Thymoglobulin
- Antilymphocyte Serum
Other Study ID Numbers
Other Study ID Numbers
- 124-01 (KWC IRB / REC No.)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.